This article has Open Peer Review reports available.
Disseminated mucormycosis (DM) after pneumonectomy: a case report
© The Author(s). 2016
Received: 29 February 2016
Accepted: 7 June 2016
Published: 22 July 2016
Mucormycosis is a kind of rare opportunistic fungal disease and the incidence of which has gradually increased. Disseminated mucormycosis (DM) is a life-threatening infection that mostly occurs in immunocompromised patients. The lung and brain are usually involved in disseminated mucormycosis, and other sites are scare. We report the first case of disseminated mucormycosis whose infection sites included lung, skin, liver, vertebra, and spinal cord that ensued after a right lung pneumonectomy in an immunocompetent patient.
A 20-year-old female underwent a right lung pneumonectomy for “lung cancer” presented with an intermittent fever for two years. A computed tomography (CT) scan showed an enclosed outstanding mass in the right chest wall. The patient also suffered from lower limb numbness and weakness, difficulty walking, and dysuria. Medical examination showed superficial feeling of the abdominal wall was decreased from the T7 and T8 level; muscle strength for both lower limbs was decreased; muscle tension of both lower limbs was also diminished. A biopsy through the right chest wall mass and thoracic mass by fistula of chest wall showed broad nonseptate hyphae with right-angle branching, consistent with mucormycosis. With titration of amphotericin B and its lipid complex, the patient recovered.
Our case showed an unusual clinical presentation of disseminated mucormycosisin an immunocompetent patient.
Mucormycosis is caused by fungi of the order Mucorales. The most common kinds of the order Mucorales which cause human infections include Rhizopus spp., Mucor spp., Lichtheimia spp., Rhizomucor spp. and Apophysomyces spp., especially the third members accounting for 70–80 % of all infectious cases . Mucormycosis is a life-threatening infection that carries a high mortality rate, despite recent advances in its diagnosis and treatment . It often occurs among immunocompromised patients, such as those with hematological malignancies, solid organ transplantation, or diabetes mellitus. Based on anatomic localization, mucormycosis can be classified as rhinocerebral, pulmonary, cutaneous, gastrointestinal, disseminated, or uncommon presentations .
Disseminated mucormycosis (DM) often involves two or more noncontinuous organ systems with zygomycetes in immunocompromised patients with hematological malignancies or organ transplantation, or in patients on deferoxamine therapy [4, 5]. The lung and brain are usually involved in DM, however, other sites are scare. In this report, we describe a case of DM in an immunocompetent young woman who had a right lung pneumonectomy almost two year prior.
The patient quickly developed type II respiratory failure. A noninvasive ventilator assisted breathing, and intravenous amphotericin B (AmB) was administered. When the dose of AmB increased to 0.5 mg/kg/day, with the cumulative dose reaching 150 mg, mental disorders (agitation, fear, etc.) and cardiac arrhythmias occurred. The adverse events disappeared when AmB was changed to liposomal AmB.
After treatment for 28 days, the patient’s body temperature became normal and her respiratory function as well as lower limb sensory and motor function recovered. The size of the right chest wall mass became smaller, and the fistula dried. Laboratory and imaging examinations indicated that the lesions of the lung, liver, and thoracic vertebrae were significantly smaller. The patient was discharged back to the local hospital for further antifungal treatment and had recovered by the 3-month follow-up exam, and plastic surgery was suggested to repair the thoracic wall.
In this report, we present a case of DM in the lung, skin, liver, vertebrae, and spinal cord after a right lung pneumonectomy. The lung and brain are usually involved in DM . The involvement of the vertebrae and spinal cord in our case has rarely been reported in DM. DM has a nonspecific manifestation, resulting in difficulties in diagnosis . In our case, it was not difficult to speculate that it first occurred in the lung, even before the pneumonectomy, as a necrotizing granulomatous mass was found. Indeed, pulmonary infection is the second most common form, accounting for more than 30 % of infections . Mucorales has a special affinity to endothelial cells, resulting in its invasion and destruction of small arteries. By attracting platelet adhesion and aggregation, Mucorales can also cause thrombosis and fatal bleeding [8, 9]. This might explain the wide dissemination of pulmonary mucormycosis in the present case.
To date, there are no known reliable clinical serological diagnostic methods for the diagnosis of DM. Microbial culture of secretions is time-consuming, with a low sensitivity and a high false-positive rate. The culture of sterile tissue may kill the pathogen because of its grinding process (a step for preparing tissue culture samples), which results in a low rate of positive cultures . Therefore, the gold standard for the diagnosis of DM relies on the characteristic mycelium and pathological changes of the biopsy. The histopathological characteristics for Mucorales is a wide (6–25) μm in diameter, rarely separating hyphae and have irregular or right angle branch. The diagnosis of pulmonary mucormycosis in this report was based on histopathology.
DM generally occurs in severely immunocompromised patients: it represents 1.6 % of all invasive fungal infections and is predominant in immunosuppressed patients with risk factors . Recently, the incidence has increased significantly, even in immunocompetent patients . Our report describes DM in an immunocompetent patient. DM is associated with a mortality rate of approximately 100 %, but successful treatment has been reported [12–14]. Successful treatment of DM requires a rapid diagnosis, reversal of predisposing factors, aggressive surgical excision, and antifungal therapy . AmB or its lipid complex remains the first choice for treatment . In the present case, after titrating the dose to avoid adverse effects, the patient recovered quickly.
Clinicians need raise awareness that DM should also be regarded in immunocompetent individuals, especially those with pulmonary mucormycosis. Retrospective studies regarding the morbidity of DM in immunocompetent individuals in the future might be necessary in order to understand its epidemiology.
AmB, amphotericin B; CT, computed tomography; DM, disseminated mucormycosis; GM, glactomannan; MRI, magnetic resonance imaging
This study was supported by A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD,JX10231802).
Availability of data and materials
All the data supporting our fin dings is contained within the manuscript.
QW and BL designed the study, wrote the manuscript, participated in literature search, and made figures and tables. YDY conceived of the study, and participated in its design and coordination and helped to revised the manuscript critically for important content. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Ethics approval and consent to participate
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? Clin Microbiol Infect. 2014;20 Suppl 6:74–81.View ArticlePubMedGoogle Scholar
- Camara-Lemarroy CR, González-Moreno EI, Rodríguez-Gutiérrez R, Rendón-Ramírez EJ, Ayala-Cortés AS, Fraga-Hernández ML, et al. Clinical Features and Outcome of Mucormycosis. Interdiscip Perspect Infect Dis. 2014;2014:1–5.Google Scholar
- Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54 Suppl 1:S23–34.View ArticleGoogle Scholar
- Lee D-G, Choi J-H, Choi S-M, Yoo J-H, Kim Y-J, Min C-K, et al. Two cases of disseminated mucormycosis in patients following allogeneic bone marrow transplantation. J Korean Med Sci. 2002;17(3):403–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Gupta KL, Joshi K, Pereira BJ, Singh K. Disseminated mucormycosis presenting with acute renal failure. Postgrad Med J. 1987;63(738):297–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Pak J, Tucci VT, Vincent AL, Sandin RL, Greene JN. Mucormycosis in immunochallenged patients. J Emerg Trauma Shock. 2008;1(2):106–13.View ArticlePubMedPubMed CentralGoogle Scholar
- McAdams HP, Rosado de Christenson M, Strollo DC, Patz EF. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol. 1997;168(6):1541–8.View ArticlePubMedGoogle Scholar
- Groll AH, Walsh TJ. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2001;7 Suppl 2:8–24.Google Scholar
- Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13(2):236–301.View ArticlePubMedPubMed CentralGoogle Scholar
- Yan D, Dong H, Shan B. Progress of epidemiology and diagnosis of invasive fungal infections. Progress of Microbiology Immunology. 2009;37(1):67–71.Google Scholar
- Pozo Laderas JC, Pontes Moreno A, Pozo Salido C, Robles Arista JC, Linares Sicilia MJ. Disseminated mucormycosis in immunocompetent patients: A disease that also exists. Rev Iberoam Micol. 2015;32(2):63–70.View ArticlePubMedGoogle Scholar
- Rickerts V, Atta J, Herrmann S, Jacobi V, Lambrecht E, Bialek R, et al. Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia. Mycoses. 2006;49 Suppl 1:27–30.View ArticlePubMedGoogle Scholar
- Mantadakis E, Samonis G. Clinical presentation of zygomycosis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2009;15 Suppl 5:15–20.Google Scholar
- Maury S, Leblanc T, Feuilhade M, Molina JM, Schaison G. Successful treatment of disseminated mucormycosis with liposomal amphotericin B and surgery in a child with leukemia. Clin Infect Dis Off Publ Infect Dis Soc Am. 1998;26(1):200–2.View ArticleGoogle Scholar
- Alacacioglu I, Kargi A, Ozcan MA, Piskin O, Solak C, Secil M, et al. Fatal disseminated mucormycosis in a patient with mantle cell non-Hodgkin’s lymphoma: an autopsy case. Braz J Infect Dis Off Publ Braz Soc Infect Dis. 2009;13(3):238–41.Google Scholar
- Cornely OA, Arikan-Akdag li S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, et al. ESCM ID and ECMM joint clini cal guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl3):5–26.View ArticlePubMedGoogle Scholar